|
1
|
La Porta CA: Mechanism of drug sensitivity
and resistance in melanoma. Curr Cancer Drug Targets. 9:391–397.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nath K, Nelson DS, Ho AM, Lee SC, Darpolor
MM, Pickup S, Zhou R, Heitjan DF, Leeper DB and Glickson JD: (31) P
and (1) H MRS of DB-1 melanoma xenografts: Lonidamine selectively
decreases tumor intracellular pH and energy status and sensitizes
tumors to melphalan. NMR Biomed. 26:98–105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang G, Li RH, Sun C, Jia HY, Lei TC and
Liu YQ: Efficacy and safety between temozolomide alone and
temozolomide-based double therapy for malignant melanoma: A
meta-analysis. Tumour Biol. 35:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Plummer ER, Middleton MR, Jones C, Olsen
A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson
AJ, et al: Temozolomide pharmacodynamics in patients with
metastatic melanoma: DNA damage and activity of repair enzymes
O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Clin Cancer Res. 11:3402–3409. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang G, Li LT, Xin Y, Zhang L, Liu YQ and
Zheng JN: Strategy for reversing resistance to temozolomide in
malignant melanoma. Curr Med Chem. 19:3886–3892. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang G, Liu YQ, Wei ZP, Pei DS, Mao LJ
and Zheng JN: Enhanced anti-tumor activity by the combination of a
conditionally replicating adenovirus mediated interleukin-24 and
dacarbazine against melanoma cells via induction of apoptosis.
Cancer Lett. 294:220–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian H, Zhang DF, Zhang BF, Li HZ, Zhang
Q, Li LT, Pei DS and Zheng JN: Melanoma differentiation associated
gene-7/interleukin-24 induces caspase-3 denitrosylation to
facilitate the activation of cancer cell apoptosis. J Interferon
Cytokine Res. 35:157–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dent P, Yacoub A, Hamed HA, Park MA, Dash
R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, et al: The
development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther.
128:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Emdad L, Lebedeva IV, Su ZZ, Gupta P,
Sauane M, Dash R, Grant S, Dent P, Curiel DT, Sarkar D and Fisher
PB: Historical perspective and recent insights into our
understanding of the molecular and biochemical basis of the
antitumor properties of mda-7/IL-24. Cancer Biol Ther. 8:391–400.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng M, Bocangel D, Ramesh R, Ekmekcioglu
S, Poindexter N, Grimm EA and Chada S: Interleukin-24 overcomes
temozolomide resistance and enhances cell death by down-regulation
of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Mol Cancer Ther. 7:3842–3851. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu XY: Targeting gene-virotherapy of
cancer and its prosperity. Cell Res. 16:879–886. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu XY, Li HG, Zhang KJ and Gu JF:
Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in
both cancer gene therapy and cancer virotherapy. Curr Pharm
Biotechnol. 13:1761–1767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He
L, Wang Y, Zhang J, Zhang Z, Huiwang J, et al: Potent antitumor
activity of oncolytic adenovirus expressing mda-7/IL-24 for
colorectal cancer. Hum Gene Ther. 16:845–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang ZY, Wang LQ, Fu CF, Li X, Cui ZL,
Zhang JY, Xue SH, Sun N and Xu F: Combination of targeting
gene-viro therapy with recombinant Fowl-pox viruses with HN and VP3
genes on mouse osteosarcoma. Eur Rev Med Pharmacol Sci. 17:767–776.
2013.PubMed/NCBI
|
|
15
|
Jiang G, Jiang AJ, Cheng Q, Tian H, Li LT
and Zheng JN: A dual-regulated oncolytic adenovirus expressing
interleukin-24 sensitizes melanoma cells to temozolomide via the
induction of apoptosis. Tumour Biol. 34:1263–1271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou X, Xie G, Wang S, Wang Y, Zhang K,
Zheng S, Chu L, Xiao L, Yu Y, Zhang Y and Liu X: Potent and
specific antitumor effect for colorectal cancer by CEA and Rb
double regulated oncolytic adenovirus harboring ST13 gene. PLos
One. 7:e475662012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang G, Zhang L, Xin Y, Pei DS, Wei ZP,
Liu YQ and Zheng JN: Conditionally replicating adenoviruses
carrying mda-7/IL-24 for cancer therapy. Acta Oncol. 51:285–292.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao L, Dong A, Gu J, Liu Z, Zhang Y,
Zhang W, Wang Y, He L, Qian C, Qian Q and Liu X: The antitumor
activity of TRAIL and IL-24 with replicating oncolytic adenovirus
in colorectal cancer. Cancer Gene Ther. 13:1011–1022. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qiu S, Ruan H, Pei Z, Hu B, Lan P, Wang J,
Zhang Z, Gu J, Sun L, Qian C, et al: Combination of targeting
gene-virotherapy with 5-FU enhances antitumor efficacy in malignant
colorectal carcinoma. J Interferon Cytokine Res. 24:219–230. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Berger A, Quast SA, Plötz M, Hein M, Kunz
M, Langer P and Eberle J: Sensitization of melanoma cells for death
ligand-induced apoptosis by an indirubin derivative-Enhancement of
both extrinsic and intrinsic apoptosis pathways. Biochem Pharmacol.
81:71–81. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kong XJ, Duan LJ, Qian XQ, Xu D, Liu HL,
Zhu YJ and Qi J: Tumor-suppressive microRNA-497 targets IKKβ to
regulate NF-κB signaling pathway in human prostate cancer cells. Am
J Cancer Res. 5:1795–1804. 2015.PubMed/NCBI
|
|
22
|
Wilczynski J, Duechler M and Czyz M:
Targeting NF-κB and HIF-1 pathways for the treatment of cancer:
Part I. Arch Immunol Ther Exp (Warsz). 59:289–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
